申请人:AstraZeneca AB
公开号:US20160326143A1
公开(公告)日:2016-11-10
There is provided compounds of formula I,
wherein E
1
, E
2
, E
3
, E
4
, L
1
, Y
1
, Y
2
, Y
3
, R
a
and z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C
4
synthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.